Copy to clipboard 
Lincotek Medical was granted FDA 510(k) clearance for the company’s SpineLinc Anterior Cervical Implant System.
With multiple footprints, device heights and lordosis angles, SpineLinc’s body makes use of the additive-manufactured Lincotek Bonepore 3D Titanium Porous Structure Technology, characterized by the company’s FDA master file. The product also contains machined plate and screw components and is offered with single-use instruments designed to be compatible with the needs of Ambulatory Surgical Centers. It is sterile packaged in Lincotek’s facility in Memphis, Tennessee.
“This new approval is great news for OEMs, as it reduces time to market,” observes Troy Walters, the Product Development Director of Lincotek’s Medical Division. “SpineLinc demonstrates our understanding of customers’ need for market-ready solutions and the critical importance of acting quickly. By aligning our expertise with their priorities, we can transform ideas into commercial success faster and more efficiently.”
Francesco Bucciotti, Head of Global and Business Development at Lincotek’s Medical Division, added: “The 510(k) approval by FDA is an important landmark, because SpineLinc has such a great potential having been engineered with OEMs, surgeons and patients in mind.”
The new product is available to OEMs for private labelling and can also be used as a predicate device by orthopedic manufacturers to improve the speed of product development for similar devices.
Source: Lincotek
